TOP-5 Price Targets of Analysts on 23.01.25
Reading Time: 2 minutes
Rigel Pharmaceuticals [US7665597024]: H.C. Wainwright reaffirms Buy rating with a price target of 57 USD (161% upside potential) The progress in clinical trials, particularly the Phase-1 study for fostamatinib in sickle cell anemia, is very promising. Additionally, Rigel's strong commercial performance, especially with products like Tavalisse, Rezlidhia, and Gavreto, shows that the company is well positioned, according to Wainwright. The company's strong forecast, with expected total revenue of 200–210 million USD for fiscal year 2025, is also...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
